CRCX4-targeted nanocarriers for triple negative breast cancers

  • chair:

    Misra, A. C. / Luker, K. E. / Durmaz, H. / Luker, G.D. / Lahann, J. (2015)
  • place:

    Biomacromolecules 6 (2015), 2412-2417
  • Date: August 2015

Abstract

CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1′-[1,4-phenylenebis-(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4.
Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4signaling.
This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies.